Netflix’s $72 Billion Warner Bros Discovery Deal Reshapes the Entertainment Landscape 
Boeing Executive Says Trump’s Equity Stake Plan Won’t Target Major Defense Contractors 
Airbus Faces Pressure After November Deliveries Dip Amid Industrial Setback 
Airline Loyalty Programs Face New Uncertainty as Visa–Mastercard Fee Settlement Evolves 
Firelight Launches as First XRP Staking Platform on Flare, Introduces DeFi Cover Feature 
IKEA Expands U.S. Manufacturing Amid Rising Tariffs and Supply Chain Strategy Shift 
U.S.-EU Tensions Rise After $140 Million Fine on Elon Musk’s X Platform 
EU Prepares Antitrust Probe Into Meta’s AI Integration on WhatsApp 
Allegiant Air Faces Union Block in Bid for Foreign Pilots’ Green Cards Amid Staffing Challenges 
Southwest Airlines Has $11 Million Fine Waived as USDOT Cites Operational Improvements 
Tesla Expands Affordable Model 3 Lineup in Europe to Boost EV Demand 
Rio Tinto Raises 2025 Copper Output Outlook as Oyu Tolgoi Expansion Accelerates 
GM Issues Recall for 2026 Chevrolet Silverado Trucks Over Missing Owner Manuals 
Amazon Italy Pays €180M in Compensation as Delivery Staff Probe Ends 
Spirit Airlines Reverses Pilot Furlough Plans Amid Updated Staffing Outlook 
Hikvision Challenges FCC Rule Tightening Restrictions on Chinese Telecom Equipment 
Lockheed Martin Secures $1.14 Billion Contract Boost for F-35 Production 
Illumina Inc. is selling its cancer test developer, Grail, following its series of antitrust conflicts. The company is a known maker of gene-sequencing machines, and on Sunday, Dec. 17, it revealed its decision to divest this unit, which it bought in 2021 for $7.1 billion.
According to The New York Times, Illumina's move to divest its Grail unit came two days after the company recently lost in a court battle. It made an appeal, but the federal court largely sided with the Federal Trade Commission when it upheld the antitrust regulator's ruling that Illumina must sell its Grail on antitrust grounds.
Obstruction in Europe
It was reported that Illumina's deal for Grail was also not cleared in Europe, and it has, in fact, faced a roadblock there, too. In September last year, the EU said it would block the acquisition. The company publicly admitted that it had been unsuccessful with its appeals for the Grail deal, and this has led to the decision to divest the start-up.
At any rate, the company's troubles started when it went ahead and purchased the cancer test developer despite the complaint from the U.S. FTC. The commission argued that the buyout would reduce innovation in the American market as well as increase prices.
Execution of Illumina's GRAIL's Sale
The biotechnology company, headquartered in San Diego, California, said that its sale of GRAIL is set to be executed via a third-party or capital markets transaction that is in line with the European Commission's (EU) divestiture order. Illumina aims to finalize the terms of the deal by the end of the second quarter of 2024.
"We are committed to an expeditious divestiture of GRAIL in a manner that allows its technology to continue benefitting patients," Illumina's chief executive officer, Jacob Thaysen, said in a press release. "The management team and I continue to focus on our core business and supporting our customers. I am confident in Illumina's opportunities and our long-term success."
Photo by: Illumina Press Release
